Compare HAS & ITRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HAS | ITRM |
|---|---|---|
| Founded | 1923 | 2015 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Recreational Games/Products/Toys | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.1B | 24.3M |
| IPO Year | N/A | 2018 |
| Metric | HAS | ITRM |
|---|---|---|
| Price | $87.23 | $0.36 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 11 | 1 |
| Target Price | ★ $88.55 | $9.00 |
| AVG Volume (30 Days) | ★ 1.5M | 919.6K |
| Earning Date | 02-19-2026 | 02-06-2026 |
| Dividend Yield | ★ 3.21% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $4,357,000,000.00 | $390,000.00 |
| Revenue This Year | $10.24 | N/A |
| Revenue Next Year | $5.62 | $193.01 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 0.79 | N/A |
| 52 Week Low | $49.00 | $0.26 |
| 52 Week High | $87.38 | $2.10 |
| Indicator | HAS | ITRM |
|---|---|---|
| Relative Strength Index (RSI) | 71.52 | 45.05 |
| Support Level | $81.65 | $0.26 |
| Resistance Level | $82.98 | $0.37 |
| Average True Range (ATR) | 1.48 | 0.04 |
| MACD | 0.44 | 0.01 |
| Stochastic Oscillator | 87.92 | 65.61 |
Hasbro is a branded play company providing children and families around the world with entertainment offerings based on a world-class brand portfolio. From toys and games to television programming, motion pictures, and a licensing program, Hasbro reaches customers by leveraging its well-known brands such as Transformers, Nerf, and Magic: The Gathering. The firm acquired EOne in 2019, bolting on popular family properties like Peppa Pig and PJ Masks, and since has divested noncore lines from the tie-up. Furthermore, the addition of Dungeons & Dragons Beyond in 2022, offers the firm access to 19 million digital tabletop players.
Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.